Related Experiment Video
Updated: Oct 22, 2025
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Mutation Status and Immunohistochemical Correlation of EGFR Mutations in Gastrointestinal Stromal Tumors
H Ozkayalar1, M C Ergoren2,3, G Tuncel2,3
1Department of Pathology, Faculty of Medicine, Near East University, Northern Nicosia, Cyprus.
Abstract:
Being one of the leading causes of cancer deaths worldwide and their resistance to conventional treatment methods, made gastrointestinal stromal tumors (GISTs) one of the hot topics in medical research areas in the past decade. To investigate molecular alterations underlying the tumor is of great importance to be able to develop new, targeted treatment options. In this study, GIST samples obtained from 40 Turkish patients were analyzed for actionable epidermal growth factor receptor (EGFR) mutations that are related to treatment regimes in non small cell lung cancer (NSCLC) to understand whether EGFR expression is altered in GISTs. Established alterations in EGFR can make the use of tyrosine kinase inhibitors possible, which are currently used in cancer therapy, especially in NSCLC. Our results indicated that EGFR mutations are rare in GISTs. Further research is needed to sequence whole coding regions of the gene to investigate new actionable mutations in EGFR in an increased sample size.
Insights
Gastrointestinal stromal tumors (GISTs) rarely exhibit epidermal growth factor receptor (EGFR) mutations. This finding suggests limited utility of EGFR-targeted therapies, like tyrosine kinase inhibitors, for GIST treatment, necessitating further research into other molecular alterations.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Gastrointestinal stromal tumors (GISTs) are a significant cause of cancer mortality globally.
- GISTs often display resistance to conventional cancer treatments, driving research into targeted therapies.
- Understanding molecular alterations in GISTs is crucial for developing novel treatment strategies.
Purpose of the Study:
- To investigate the presence and significance of actionable epidermal growth factor receptor (EGFR) mutations in GISTs.
- To explore the potential for using EGFR-targeted therapies, such as tyrosine kinase inhibitors, in GIST treatment.
- To determine if EGFR expression is altered in GIST samples from Turkish patients.
Main Methods:
- Analysis of GIST samples from 40 Turkish patients.
- Focus on actionable mutations in the epidermal growth factor receptor (EGFR) gene.
- Comparison with known EGFR alterations in non-small cell lung cancer (NSCLC) treatment.
Main Results:
- Epidermal growth factor receptor (EGFR) mutations were found to be rare in the analyzed GIST samples.
- The study indicates a low prevalence of actionable EGFR mutations in this GIST cohort.
- Current findings suggest that EGFR-targeted therapies may have limited applicability in GISTs.
Conclusions:
- EGFR mutations are infrequent in gastrointestinal stromal tumors (GISTs).
- Further comprehensive research, including sequencing of entire coding regions and larger sample sizes, is required.
- Future studies should aim to identify novel actionable mutations in EGFR for potential GIST therapeutic targets.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
